In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Biologics ...

“ Psoriasis is an inflammatory skin disorder, due to an overactive immune system,” said Dr. Omar Noor. “That over active immune system produces inflammation in the skin that causes the skin to develop ...

Uwe Gudat, M.D., Chief Medical Officer, Biocon Biologics said ... in the treatment of moderate to severe chronic plaque psoriasis and by extension the other indications for which Ustekinumab ...